查看文章

High concentrations of subtype 2 somatostatin tumor receptors (sst₂) are expressed in numerous tumors, enabling primary and metastatic masses to be localized by scintigraphy after injecting ¹¹¹In-labeled somatostatin analogue octreotide. In addition to neuroendocrine tumors, somatostatin receptors have been identified on cancers of the central nervous system, breast, lung, and lymphatic tissue, and the use of radionuclide-labeled somatostatin analogues appeared promising for therapy as well as for diagnosis of such malignancies. The somatostatin analogue [DOTA-_DPhe¹-Tyr³] octreotide (DOTATOC) possesses favorable characteristics for its potential therapeutic use in that it shows high affinity for sst₂, moderately high affinity for sst₅, and intermediate affinity for sst₃, high hydrophilicity, stable and facile labeling with ¹¹¹In and ⁹⁰Y. We began to investigate the potential therapeutic applications of ⁹⁰Y …